The researchers examined 37 recurrently mutated genes in AML using next-generation sequencing.
All articles by Agata Boxe
Initial therapy with pembrolizumab may result in comparable overall survival as standard chemotherapy in patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.
Latest News Your top articles for TuesdayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses